{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:14:49Z","timestamp":1790115289064,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jacl.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T02:34:16Z","timestamp":1634870056000},"page":"814-821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evolocumab in patients with homozygous familial hypercholesterolemia in India"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-4077","authenticated-orcid":false,"given":"Sandeep","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JPS","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shammana","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3762-2618","authenticated-orcid":false,"given":"Vimal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2021.10.003_bib0001","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2021.10.003_bib0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.15420\/ecr.2014.9.2.76","article-title":"Current treatment of familial hypercholesterolaemia","volume":"9","author":"Lambert","year":"2014","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0003","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2021.10.003_bib0004","article-title":"Familial hypercholesterolaemia: identification and management","author":"Health","year":"2008","journal-title":"Clinical guideline"},{"key":"10.1016\/j.jacl.2021.10.003_bib0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomized, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2021.10.003_bib0006","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2021.10.003_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0008","unstructured":"Repatha [package insert]. Thousand Oaks, CA: Amgen Inc; 2015."},{"key":"10.1016\/j.jacl.2021.10.003_bib0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2021.10.003_bib0010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(87)90079-1","article-title":"Duplication of seven exons in LDL receptor gene caused by Alu-Alu recombination in a subject with familial hypercholesterolemia","volume":"48","author":"Lehrman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.jacl.2021.10.003_bib0011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2008.07.005","article-title":"Update of Japanese common LDLR gene mutations and their phenotypes: mild type mutation L547V might predominate in the Japanese population","volume":"203","author":"Miyake","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2021.10.003_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0925-4439(93)90156-U","article-title":"Identification of two new LDL-receptor mutations causing homozygous familial hypercholesterolemia in a South African of Indian origin","volume":"1182","author":"Rubinsztein","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2021.10.003_bib0013","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/gim.2017.151","article-title":"Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis","volume":"20","author":"Chora","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jacl.2021.10.003_bib0014","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2021.10.003_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH Trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0016","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jacc.2017.06.058","article-title":"Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations","volume":"70","author":"Stein","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0017","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0018","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2021.10.003_bib0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacl.2019.12.010","article-title":"Genetic analysis of familial hypercholesterolemia in Asian Indians: a single-center study","volume":"14","author":"Setia","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2021.10.003_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2016.10.028","article-title":"Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations","volume":"255","author":"Setia","year":"2016","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421002543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421002543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:42Z","timestamp":1761831402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287421002543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1933287421002543"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2021.10.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolocumab in patients with homozygous familial hypercholesterolemia in India","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}